JPH03127726A - Pasting agent - Google Patents
Pasting agentInfo
- Publication number
- JPH03127726A JPH03127726A JP1267313A JP26731389A JPH03127726A JP H03127726 A JPH03127726 A JP H03127726A JP 1267313 A JP1267313 A JP 1267313A JP 26731389 A JP26731389 A JP 26731389A JP H03127726 A JPH03127726 A JP H03127726A
- Authority
- JP
- Japan
- Prior art keywords
- adhesive
- drug
- adhesive layer
- patch
- force value
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001070 adhesive effect Effects 0.000 claims abstract description 193
- 239000000853 adhesive Substances 0.000 claims abstract description 192
- 230000003014 reinforcing effect Effects 0.000 claims abstract description 28
- 239000012765 fibrous filler Substances 0.000 claims abstract description 23
- 230000009477 glass transition Effects 0.000 claims abstract description 14
- 239000012790 adhesive layer Substances 0.000 claims description 91
- 229920000642 polymer Polymers 0.000 claims description 55
- 239000010410 layer Substances 0.000 claims description 14
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 13
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 7
- 229940079593 drug Drugs 0.000 abstract description 94
- 239000003814 drug Substances 0.000 abstract description 94
- 239000003795 chemical substances by application Substances 0.000 abstract description 14
- 239000000203 mixture Substances 0.000 abstract description 10
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 abstract description 4
- 239000003365 glass fiber Substances 0.000 abstract description 4
- 239000004744 fabric Substances 0.000 abstract description 3
- 229920000058 polyacrylate Polymers 0.000 abstract description 3
- 239000003381 stabilizer Substances 0.000 abstract description 3
- 229910000085 borane Inorganic materials 0.000 abstract description 2
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- -1 acrylic ester Chemical class 0.000 description 24
- 238000000034 method Methods 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000000178 monomer Substances 0.000 description 12
- 239000000835 fiber Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 8
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 8
- 239000004014 plasticizer Substances 0.000 description 8
- 239000000306 component Substances 0.000 description 7
- 239000013078 crystal Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- JHPBZFOKBAGZBL-UHFFFAOYSA-N (3-hydroxy-2,2,4-trimethylpentyl) 2-methylprop-2-enoate Chemical compound CC(C)C(O)C(C)(C)COC(=O)C(C)=C JHPBZFOKBAGZBL-UHFFFAOYSA-N 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000000704 physical effect Effects 0.000 description 5
- 229920000139 polyethylene terephthalate Polymers 0.000 description 5
- 239000005020 polyethylene terephthalate Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 238000007718 adhesive strength test Methods 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 229960000905 indomethacin Drugs 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229920006222 acrylic ester polymer Polymers 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002685 polymerization catalyst Substances 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000005396 acrylic acid ester group Chemical group 0.000 description 2
- 229920006243 acrylic copolymer Polymers 0.000 description 2
- 239000002390 adhesive tape Substances 0.000 description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 2
- FUSUHKVFWTUUBE-UHFFFAOYSA-N buten-2-one Chemical compound CC(=O)C=C FUSUHKVFWTUUBE-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 239000011256 inorganic filler Substances 0.000 description 2
- 229910003475 inorganic filler Inorganic materials 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- ANISOHQJBAQUQP-UHFFFAOYSA-N octyl prop-2-enoate Chemical compound CCCCCCCCOC(=O)C=C ANISOHQJBAQUQP-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920002239 polyacrylonitrile Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000002759 woven fabric Substances 0.000 description 2
- PUGOMSLRUSTQGV-UHFFFAOYSA-N 2,3-di(prop-2-enoyloxy)propyl prop-2-enoate Chemical compound C=CC(=O)OCC(OC(=O)C=C)COC(=O)C=C PUGOMSLRUSTQGV-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- ROGIWVXWXZRRMZ-UHFFFAOYSA-N 2-methylbuta-1,3-diene;styrene Chemical compound CC(=C)C=C.C=CC1=CC=CC=C1 ROGIWVXWXZRRMZ-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 229920000049 Carbon (fiber) Polymers 0.000 description 1
- 102100037709 Desmocollin-3 Human genes 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 101000880960 Homo sapiens Desmocollin-3 Proteins 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- YIVJZNGAASQVEM-UHFFFAOYSA-N Lauroyl peroxide Chemical compound CCCCCCCCCCCC(=O)OOC(=O)CCCCCCCCCCC YIVJZNGAASQVEM-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 229920007962 Styrene Methyl Methacrylate Polymers 0.000 description 1
- 239000002174 Styrene-butadiene Substances 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 150000003926 acrylamides Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229940075522 antidotes Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- ZFMQKOWCDKKBIF-UHFFFAOYSA-N bis(3,5-difluorophenyl)phosphane Chemical compound FC1=CC(F)=CC(PC=2C=C(F)C=C(F)C=2)=C1 ZFMQKOWCDKKBIF-UHFFFAOYSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- MTAZNLWOLGHBHU-UHFFFAOYSA-N butadiene-styrene rubber Chemical compound C=CC=C.C=CC1=CC=CC=C1 MTAZNLWOLGHBHU-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000004917 carbon fiber Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229920006026 co-polymeric resin Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- GTBGXKPAKVYEKJ-UHFFFAOYSA-N decyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCOC(=O)C(C)=C GTBGXKPAKVYEKJ-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- MIMDHDXOBDPUQW-UHFFFAOYSA-N dioctyl decanedioate Chemical compound CCCCCCCCOC(=O)CCCCCCCCC(=O)OCCCCCCCC MIMDHDXOBDPUQW-UHFFFAOYSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Chemical compound CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 235000010985 glycerol esters of wood rosin Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- HPKLIMZLKHZMQW-UHFFFAOYSA-N hexan-1-ol prop-2-enoic acid Chemical compound OC(=O)C=C.OC(=O)C=C.CCCCCCO HPKLIMZLKHZMQW-UHFFFAOYSA-N 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N hexanedioic acid Natural products OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical class CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- OMNKZBIFPJNNIO-UHFFFAOYSA-N n-(2-methyl-4-oxopentan-2-yl)prop-2-enamide Chemical compound CC(=O)CC(C)(C)NC(=O)C=C OMNKZBIFPJNNIO-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012766 organic filler Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000005426 pharmaceutical component Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- JNTOKFNBDFMTIV-UHFFFAOYSA-N propyl nitrate Chemical compound CCCO[N+]([O-])=O JNTOKFNBDFMTIV-UHFFFAOYSA-N 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000011115 styrene butadiene Substances 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
【発明の詳細な説明】
(産業上の利用分野)
本発明は、多量の薬剤が溶解され、そして薬剤の放出性
が高い粘着剤層が設けられた貼付剤に関する。この貼付
剤の粘着剤層は、皮膚への貼付性に優れ、粘着性および
凝集性のバランスが良好で−
ある。DETAILED DESCRIPTION OF THE INVENTION (Field of Industrial Application) The present invention relates to a patch in which a large amount of a drug is dissolved and is provided with an adhesive layer that has a high drug release property. The adhesive layer of this patch has excellent adhesion to the skin and a good balance between adhesiveness and cohesiveness.
(従来の技術)
薬剤を含有する粘着剤の粘着性を利用して皮膚に貼付し
、薬剤の薬効を発現させる貼付剤は、以前から多く提案
されている。この種の貼付剤は、一般に、裏打支持体層
と、粘着剤および薬剤を含有する粘着剤層とから構成さ
れる。薬剤は、粘着剤層に、溶解状態、分散状態、マイ
クロカプセル化された分散状態、隔壁容器中に封入され
た状態などで存在する。このような貼付剤の例には、抗
炎症性コルチコステロイドおよび特定のアクリル系共重
合体を含有する接着層と基材とからなる皮膚疾患治療貼
付剤(特公昭52−18813号公報、帝人社)、抗炎
症性ステロイドおよびアクリル系共重合体を含有する感
圧接着性材料を、不透過性支持体フィルム上に形成した
接着テープ(特公昭52−31405号公報、イーライ
・リリー社)、裏打部材および感圧接着剤層を有し、さ
らに薬剤貯蔵層が設けられた医薬包帯(特公昭54−1
6566号公報、スチーブン・デビット・ゴールドビイ
)、特定のアク2−
リル酸エステル共重合物を主体とする薬物含有貼着剤層
と担持体とを構成要素とする医薬部材(特開昭56−4
5412号、日東電工社)、およびガラス転移温度(T
g)が−70’C〜−10℃の重合物およびプロパチル
ニトレートを含む基剤を担持体上に形成してなる医薬製
剤(特開昭57−183714号公報、日東電工社)が
挙げられる。(Prior Art) Many patches have been proposed for a long time, which are applied to the skin by utilizing the adhesive properties of an adhesive containing a drug to exert the medicinal effects of the drug. This type of patch generally consists of a backing support layer and an adhesive layer containing an adhesive and a drug. The drug exists in the adhesive layer in a dissolved state, a dispersed state, a dispersed state in microcapsules, a state enclosed in a septum container, or the like. Examples of such patches include skin disease treatment patches comprising a base material and an adhesive layer containing an anti-inflammatory corticosteroid and a specific acrylic copolymer (Japanese Patent Publication No. 52-18813, Teijin (Japanese Patent Publication No. 52-31405, Eli Lilly & Co.), an adhesive tape formed of a pressure-sensitive adhesive material containing an anti-inflammatory steroid and an acrylic copolymer on an impermeable support film A medical bandage having a backing member and a pressure-sensitive adhesive layer, and further provided with a drug storage layer (Special Publication No. 54-1
No. 6566, Stephen David Goldby), a pharmaceutical component comprising a carrier and a drug-containing adhesive layer mainly composed of a specific ac-2-lylic acid ester copolymer (Japanese Unexamined Patent Application Publication No. 1983-1989). 4
No. 5412, Nitto Denko Corporation), and glass transition temperature (T
g) is a pharmaceutical preparation formed by forming a base containing a polymer having a temperature of -70'C to -10C and propyl nitrate on a carrier (Japanese Unexamined Patent Publication No. 57-183714, Nitto Denko Corporation). It will be done.
しかしながら、これらの貼付剤で用いられている粘着剤
の物理的性質は、他の通常の粘着テープ(例えば、一般
の文具テープ、包装用テープ、絶縁ビニルなどのプラス
チックテープ、工業用テープ)に用いられる粘着剤と全
く変わらない。例えば、この種の粘着剤のガラス転移温
度(Tg)は、はぼ−70℃〜−15℃の範囲である。However, the physical properties of the adhesive used in these patches are similar to those used in other conventional adhesive tapes (e.g., general stationery tape, packaging tape, plastic tape such as insulating vinyl, industrial tape). It is no different from the adhesive used. For example, the glass transition temperature (Tg) of this type of adhesive is in the range of -70°C to -15°C.
この範囲をはずれるガラス転移温度(Tg)をもった粘
着剤は、粘着性や保持性などの点で、実用に供し得ない
と考えられている。しかし、この範囲のTgを有する粘
着剤は、一般に薬剤との相溶性が悪いため充分な量の薬
剤を含有し得ない。多量の薬剤を粘着剤中に含有させよ
うと試みても、この粘着剤は薬剤を充一
分に溶解し得ない。溶解した少量の薬剤も粘着剤中に移
行・拡散されにくい。それゆえ、粘着剤層の薬剤放出性
は低く、薬剤が皮膚面に到達して皮膚に吸収される割合
が小さい。従って、このような粘着剤層を有する貼付剤
を皮膚に適用しても、充分な薬効が得られない。Adhesives with glass transition temperatures (Tg) outside this range are considered to be unsuitable for practical use in terms of adhesiveness, retention, and the like. However, adhesives having a Tg in this range generally have poor compatibility with drugs and cannot contain a sufficient amount of drugs. Even if an attempt is made to incorporate a large amount of drug into an adhesive, the adhesive cannot sufficiently dissolve the drug. Even a small amount of dissolved drug is difficult to migrate and diffuse into the adhesive. Therefore, the drug release property of the adhesive layer is low, and the rate at which the drug reaches the skin surface and is absorbed into the skin is small. Therefore, even if a patch having such an adhesive layer is applied to the skin, sufficient medicinal efficacy cannot be obtained.
(発明が解決しようとする問題点)
本発明は上記従来の問題点を解決するものであり、その
目的は、多量の薬剤が溶解され、そして薬剤の放出性が
高い粘着剤層を有する貼付剤を提供することにある。本
発明の他の目的は、皮膚への馴染みが良好であり、付着
性に優れる貼付剤を提供することにある。本発明のさら
に他の目的は、粘着性および凝集性のバランスが良好な
貼付剤を提供することにある。(Problems to be Solved by the Invention) The present invention solves the above-mentioned conventional problems, and its purpose is to provide a patch that dissolves a large amount of drug and has an adhesive layer with high drug release properties. Our goal is to provide the following. Another object of the present invention is to provide a patch that is well adapted to the skin and has excellent adhesion. Still another object of the present invention is to provide a patch with a good balance between adhesiveness and cohesiveness.
(問題点を解決するための手段)
本発明は、これまで使用されていなかったガラス転移温
度(Tg)が−71℃以下の粘着剤を用いることにより
、粘着剤と薬剤との相溶性が著しく向上しているため多
量の薬剤が粘着剤層に溶解され得=4
る;粘着剤層に溶解された薬剤は、移行・拡散しやすい
ため高い放出性を有する;この粘着剤層は皮膚への馴染
みが良好であり、粘着性や付着性に優れる(例えば、皮
膚を伸びちじみしても、貼付剤がずれにくい);そして
、この粘着剤に補強性繊維質充填剤を添加することによ
ってTgの低い粘着剤を用いる欠点が改善され、粘着剤
層の粘着性および凝集性のバランスが維持される;との
発明者の知見に基づいて完成された。(Means for Solving the Problems) The present invention uses an adhesive with a glass transition temperature (Tg) of -71°C or lower, which has not been used so far, thereby significantly improving the compatibility between the adhesive and the drug. A large amount of drug can be dissolved in the adhesive layer because of the improved adhesive layer = 4; Drugs dissolved in the adhesive layer have high release properties because they are easily transferred and diffused; It has good adhesion and excellent adhesiveness and adhesion (for example, the patch does not easily slip off even when stretched on the skin); and by adding reinforcing fibrous filler to this adhesive, the Tg The invention was completed based on the inventor's knowledge that the disadvantages of using an adhesive with low viscosity are improved, and the balance between tackiness and cohesiveness of the adhesive layer is maintained.
本発明の貼付剤は、裏打支持体層と粘着剤層とを有する
貼付剤において、該粘着剤層は、ガラス転移温度(Tg
)が−71℃以下である粘着剤、補強性繊維質充填剤、
および薬剤を含有し、該粘着剤は(メタ)アクリル酸エ
ステルポリマーから主として構成され、該粘着剤層の保
持力値(H)および粘着力値(F)は以下のa式および
b式の関係を満足し、そのことにより上記目的が達成さ
れる。The adhesive patch of the present invention has a backing support layer and an adhesive layer, and the adhesive layer has a glass transition temperature (Tg
) is -71°C or less, a reinforcing fibrous filler,
and a drug, the adhesive is mainly composed of a (meth)acrylic acid ester polymer, and the holding force value (H) and adhesive force value (F) of the adhesive layer are expressed by the following equations a and b. is satisfied, thereby achieving the above objective.
H/F>0.3(秒/g) ・・・ aF > Zo
o (g) ・・・ b本発明の貼付剤におい
て、ガラス転移温度(Tg)=5
が−71℃以下の粘着剤を用いることにより、多量の薬
剤が粘着剤に溶解され得る。粘着剤に溶解された薬剤は
、移行・拡散しやすいため、高い放出性も有する。これ
は、丁gの低い粘着剤中では、薬剤分子が自由で活発に
運動し得るためであると考えられる。このような低いT
gの粘着剤を含有する粘着剤層は、皮膚への貼付性にも
優れる。これは、この粘着剤を主として構成するポリマ
ー分子が、セグメント単位で動き易くなるためであると
推測される。さらに、Tgの低下に伴って粘着剤の凝集
力が低下するため、凝集力を維持するべく、この粘着剤
層に補強性繊維質充填剤が含有される。それにより、凝
集力の低下により粘着剤層に発生する種々の欠点(例え
ば、滲み出し、ずれ、糸引き、粘着剤の皮膚への残留)
が改善される。その結果、粘着性と凝集性のバランスが
維持された粘着剤層を有する貼付剤が得られる。さらに
、粘着剤、補強性繊維質充填剤および薬剤の組成や含有
量の選択により、目的に応じた種々の異なる物性を有す
る貼付剤が提供される。H/F>0.3 (sec/g)...aF>Zo
o (g) ... b In the patch of the present invention, by using an adhesive having a glass transition temperature (Tg) of -71°C or lower, a large amount of the drug can be dissolved in the adhesive. Since the drug dissolved in the adhesive is easily transferred and diffused, it also has high release properties. This is thought to be because drug molecules can move freely and actively in adhesives with low g. Such a low T
The adhesive layer containing the adhesive of g also has excellent adhesion to the skin. It is presumed that this is because the polymer molecules that mainly constitute this adhesive tend to move in segment units. Furthermore, since the cohesive force of the adhesive decreases as the Tg decreases, a reinforcing fibrous filler is contained in this adhesive layer in order to maintain the cohesive force. As a result, various defects that occur in the adhesive layer due to a decrease in cohesive force (e.g. oozing, shearing, stringiness, adhesive remaining on the skin)
is improved. As a result, a patch having an adhesive layer with a well-balanced adhesiveness and cohesiveness can be obtained. Furthermore, by selecting the composition and content of the adhesive, reinforcing fibrous filler, and drug, patches with various physical properties depending on the purpose can be provided.
ガラス転移温度(Tg)が−71℃以下の粘着剤を得る
には、Tgが一71℃以下の上記(メタ)アクリル酸ア
ルキルエステルポリマーを用いることがまず考えられる
。しかし、実際には、Tgが一71℃を越える上記(メ
タ)アクリル酸アルキルエステルポリマーに、Tg低下
効果を有する軟化剤(7g低下剤)などを添加すること
により、Tgが一71℃以下の粘着剤に調製される。得
られる粘着剤の物性を維持するべく、この7g低下剤の
添加量を少なくするために、Tgが一71℃以上であっ
ても一71℃に近い(メタ)アクリル酸アルキルエステ
ルポリマーが用いられる。なお、本発明で規定されるT
gは、JISK7121−1987に基づいてDSC法
により測定されたものである。In order to obtain a pressure-sensitive adhesive having a glass transition temperature (Tg) of -71°C or lower, it is first considered to use the above-mentioned (meth)acrylic acid alkyl ester polymer having a Tg of -71°C or lower. However, in reality, by adding a softening agent (7g lowering agent) that has a Tg lowering effect to the above (meth)acrylic acid alkyl ester polymer whose Tg exceeds 171°C, it is possible to lower the Tg to 171°C or lower. Prepared into adhesive. In order to maintain the physical properties of the resulting adhesive and to reduce the amount of this 7g lowering agent added, a (meth)acrylic acid alkyl ester polymer whose Tg is close to -71°C is used even if it is above -71°C. . Note that T defined in the present invention
g was measured by DSC method based on JIS K7121-1987.
本発明の貼付剤で用いられる粘着剤は、アクリル酸エス
テルポリマー メタクリル酸エステルポリマー アクリ
ル酸エステルとメタクリル酸エステルとの共重合ポリマ
ー およびそれらの混合物から主として構成される。こ
れらアクリル系ポリマーは、低刺激性または無刺激性、
皮膚への粘着7−
性、耐劣化性、多くの薬剤との相溶性、成形容易性など
に優れているため、貼付剤の粘着剤に広く用いられてい
る。アクリル酸エステルポリマーは、メタクリル酸エス
テルポリマーよりTgが低いため、好ましい。しかし、
メタクリル酸エステルポリマーも使用可能である。The adhesive used in the adhesive patch of the present invention is mainly composed of an acrylic ester polymer, a methacrylic ester polymer, a copolymer of an acrylic ester and a methacrylic ester, and a mixture thereof. These acrylic polymers are hypoallergenic or non-irritating,
It is widely used as an adhesive for patches because it has excellent adhesion to the skin, resistance to deterioration, compatibility with many drugs, and ease of molding. Acrylic ester polymers are preferred because they have a lower Tg than methacrylic ester polymers. but,
Methacrylic acid ester polymers can also be used.
用いられるアクリル酸エステルポリマーは、エステル残
基として、炭素原子数が4〜9の直鎖状アルキル基を有
するエステル、および炭素原子数が6〜9の非第3級の
分枝鎖アルキル基を有するエステルなどから形成される
。これらのアルキル基には、n−ブチル基、n−ヘキシ
ル基、n−へブチル基、n−オクチル基、n−ノニル基
、インオクチル基、2−エチルヘキシル基などがある。The acrylic acid ester polymer used has an ester having a linear alkyl group having 4 to 9 carbon atoms as an ester residue, and a non-tertiary branched alkyl group having 6 to 9 carbon atoms. It is formed from esters and the like. These alkyl groups include n-butyl, n-hexyl, n-hebutyl, n-octyl, n-nonyl, inoctyl, 2-ethylhexyl, and the like.
メタクリル酸エステルポリマーには、エステル残基とし
て、n−デシル基やn−ドデシル基などを有するエステ
ルが挙げられる。また、メタクリル酸アルキルエステル
には、炭素原子数が10〜12の直鎖状アルキル基を有
するエステルが好ましい。これらのアクリル酸アルキル
エステルおよびメタクリル酸アルキルエ=8
ステルは、ポリマー全体の70重量%以上を構成するの
が望ましい。また、このアクリル酸アルキルエステルお
よびメタクリル酸アルキルエステルのみから構成される
ポリマーのTgは、少なくとも−so’c以下であるこ
とが好ましい。The methacrylic acid ester polymer includes esters having n-decyl group, n-dodecyl group, etc. as ester residues. Further, the methacrylic acid alkyl ester is preferably an ester having a linear alkyl group having 10 to 12 carbon atoms. These acrylic acid alkyl esters and methacrylic acid alkyl esters desirably constitute 70% or more by weight of the entire polymer. Further, it is preferable that the Tg of the polymer composed only of the acrylic acid alkyl ester and the methacrylic acid alkyl ester is at least -so'c or less.
粘着剤のTgを一71℃以下に調節するために添加され
る7g低下剤には、(メタ)アクリル酸エステルポリマ
ーと相溶性のある軟化剤(または樹脂性タッキファイヤ
−)、液状可塑剤などが用いられる。The 7g lowering agent added to adjust the Tg of the adhesive to -71°C or less includes a softener (or resin tackifier) that is compatible with the (meth)acrylic acid ester polymer, a liquid plasticizer, etc. is used.
この7g低下剤には、例えば、ジブチルフタレート、ジ
オクチルフタレートのようなフタル酸エステル系可塑剤
;ジブチルセバケートのようなセバシン酸エステル系可
塑剤;ジオクチルアジペートのようなアジピン酸エステ
ル系可塑剤; トリブチルホスフェートのようなリン酸
エステル系可塑剤;ヒマシ油のような天然から得られる
グリセリントリエステル系可塑剤;オリーブ油のような
植物油;クエン酸トリエチルのようなりエン酸エステル
系可塑剤;液状ポリエーテルのような液状可塑剤;エス
テルガムのようなロジンエステル系誘導体(9−
樹脂性タッキファイヤ−); ミリスチン酸イソプロピ
ルやエイシンのような薬剤移行促進効果を有する化合物
などがある。これらの7g低下剤は、通常、上記(メタ
)アクリル酸エステルポリマー100重量部あたり、5
0重量部以下で加えられる。この7g低下剤の添加量が
多すぎると、得られた粘着剤層が軟らかくなりすぎ、充
分な凝集性が得られない。This 7g lowering agent includes, for example, phthalate ester plasticizers such as dibutyl phthalate and dioctyl phthalate; sebacate ester plasticizers such as dibutyl sebacate; adipic acid ester plasticizers such as dioctyl adipate; and tributyl. Phosphate ester plasticizers such as phosphates; naturally occurring glycerol triester plasticizers such as castor oil; vegetable oils such as olive oil; enoate ester plasticizers such as triethyl citrate; liquid plasticizers such as; rosin ester derivatives (9-resin tackifiers) such as ester gum; and compounds that have a drug transfer promoting effect such as isopropyl myristate and eisin. These 7g-lowering agents are usually used in an amount of 5% per 100 parts by weight of the above (meth)acrylic acid ester polymer.
Added at 0 parts by weight or less. If the amount of the 7g-lowering agent added is too large, the resulting adhesive layer will become too soft and sufficient cohesiveness will not be obtained.
補強性繊維質充填剤は、有機質および/または無機質の
短繊維とされる。この充填剤は、100μm以下の平均
直径、および25mm+以下(望ましくは、1mm以上
)の平均繊維長を有するのが好ましい。The reinforcing fibrous filler is made of organic and/or inorganic short fibers. Preferably, the filler has an average diameter of 100 μm or less and an average fiber length of 25 mm+ (desirably 1 mm or more).
この充填剤は、粘着剤層にて、好ましくは、5〜60重
量%の割合で含有される。5重量%を下まわると、充填
剤の添加効果が充分に得られない。60重量%を上まわ
ると、得られた粘着剤層の粘着性が低下する。無機質の
充填剤には、例えば、ガラス繊維、石綿ファイバー、炭
素繊維などがある。This filler is preferably contained in the adhesive layer in a proportion of 5 to 60% by weight. When the amount is less than 5% by weight, the effect of adding the filler cannot be sufficiently obtained. When it exceeds 60% by weight, the adhesiveness of the resulting adhesive layer decreases. Examples of inorganic fillers include glass fiber, asbestos fiber, and carbon fiber.
有機質の充填剤としては、例えば、天然または合成のセ
ルロース、ポリ塩化ビニル、ポリエステル、ポリアクリ
ロニトリル、ポリアミド(例えば、ナ1〇−
イロン)、ポリビニルアセタール、ポリエチレン、ポリ
プロピレンなどが挙げられる。これらの有機質および/
または無機質の充填剤は、高い添加効果を得るために、
2種以上が混合して用いられるのが好ましい。この充填
剤は、粘着剤との親和性を向上させるために、必要に応
じて、その表面が化学処理(主として、コーティング)
される。例えば、充填剤がガラス繊維の場合、その表面
にはボラン処理などが施される。Examples of organic fillers include natural or synthetic cellulose, polyvinyl chloride, polyester, polyacrylonitrile, polyamide (eg, nylon), polyvinyl acetal, polyethylene, polypropylene, and the like. These organic substances and/
Or, in order to obtain a high addition effect, inorganic fillers are used.
It is preferable to use a mixture of two or more kinds. The surface of this filler may be chemically treated (mainly by coating) to improve its affinity with the adhesive.
be done. For example, if the filler is glass fiber, its surface is treated with borane or the like.
本発明の貼付剤に加えられる薬剤には、例えば、鎮痛消
炎剤、ステロイドホルモン剤、抗アレルギー剤、抗ヒス
タミン剤、冠血管拡張剤、カルシウム拮抗剤、抗・殺菌
剤、抗生物質類、解毒剤、鎮咳剤、鎮痒剤、催眠剤、精
神活力剤、精神安定剤、血圧調整剤、利尿剤、ぜんそく
剤、抗てんかん剤、ホルモン分泌促進剤、抗潰瘍剤、結
石溶解剤、制癌剤、ビタミン剤、血行促進剤、麻酔剤な
どが挙げられる。Drugs added to the patch of the present invention include, for example, analgesic and anti-inflammatory agents, steroid hormones, antiallergic agents, antihistamines, coronary vasodilators, calcium antagonists, antibacterial agents, antibiotics, antidotes, and antitussives. , antipruritics, hypnotics, mental energizers, tranquilizers, blood pressure regulators, diuretics, asthmatics, antiepileptics, hormone secretagogues, antiulcer agents, stone dissolvers, anticancer agents, vitamins, blood circulation promoters , anesthetics, etc.
本発明の貼付剤の粘着剤は、アクリル酸エステルポリマ
ー メタクリル酸エステルポリマー ア1
クリル酸エステルとメタクリル酸エステルとの共重合ポ
リマーおよびそれらの混合物から主として構成されるも
のの、これらのポリマーの骨格内にて、以下のような単
官能性のモノマー単位の1種またはそれ以上が少量(例
えば、30%以下)で共重合されていてもよいニアクリ
ル酸、メタクリル酸、エステル残基がアルコキシ基また
は末端アルキル基であるポリオキシアルキレン基を有ス
る(メタ)アクリル酸エステル類、アルキル化アクリル
アミド、アルキル化メタクリルアミド、アルコキシアル
キル(メタ)アクリルアミド、酢酸ビニルなどの脂肪酸
ビニルエステル、クロトン酸、ビニルピロリドン、アル
キルビニルエーテル、(メタ)アクリロニトリル、無水
マレイン酸、フマール酸またはそのエステル、ジアセト
ンアクリルアミド、メチルビニルケトン。また、ポリマ
ーの微架橋重合を可能にするために、以下のような多官
能性モノマーが、05%以下で加えられてもよい:ヘキ
サンンオールジアクリレート、ポリアルキレングリコー
ルジメタクリレート、グリセリントリアクリレ2
−ト。これらのモノマーは、得られる粘着剤のガラス転
移温度、機械的強度、柔軟性、親水性、薬剤との親和性
、粘着性、必須モノマーとの重合性などを微調整するた
めに、加えられる。The adhesive of the patch of the present invention is mainly composed of an acrylic ester polymer, a methacrylic ester polymer, a copolymer of an acrylic ester and a methacrylic ester, and a mixture thereof. Niacrylic acid, methacrylic acid, or ester residues may be copolymerized with a small amount (for example, 30% or less) of one or more of the following monofunctional monomer units, such as an alkoxy group or a terminal alkyl group. (meth)acrylic acid esters having a polyoxyalkylene group, alkylated acrylamide, alkylated methacrylamide, alkoxyalkyl (meth)acrylamide, fatty acid vinyl esters such as vinyl acetate, crotonic acid, vinylpyrrolidone, alkyl Vinyl ether, (meth)acrylonitrile, maleic anhydride, fumaric acid or its ester, diacetone acrylamide, methyl vinyl ketone. Also, to enable slightly crosslinked polymerization of the polymer, polyfunctional monomers such as the following may be added at up to 0.5%: hexaneol diacrylate, polyalkylene glycol dimethacrylate, glycerol triacrylate. 2-g. These monomers are added to finely adjust the glass transition temperature, mechanical strength, flexibility, hydrophilicity, affinity with drugs, adhesiveness, polymerizability with essential monomers, etc. of the resulting adhesive.
本発明の貼付剤の粘着剤層には、必要に応じて、老化防
止剤、酸化防止剤、粘着性向上剤、薬剤吸収促進剤、安
定化剤、界面活性剤、染料または顔料などが添加されて
もよい。老化防止剤や安定化剤は、粘着剤、薬剤や添加
剤の老化防止および安定化のために、適量で用いられる
。本発明で用いる粘着剤は、Tgが−71’C以下であ
るため、優れた薬剤移行効果および吸収効果を有するも
のの、この効果をさらに高めるために、薬剤移行および
吸収促進剤が加えられる。また、薬剤による皮膚の湿潤
を促進するために、界面活性剤が適量で用いられる。さ
らに、粘着剤層は(メタ)アクリル酸アルキルエステル
ポリマーを主体とするものの、その物性を調整するため
に、全ポリマー成分の約30%以下の量で、このポリマ
ーに他のポリマー(例えば、ゴム成分)が添加されても
よい。The adhesive layer of the patch of the present invention may contain antioxidants, antioxidants, tackiness improvers, drug absorption promoters, stabilizers, surfactants, dyes, pigments, etc., as necessary. You can. Antiaging agents and stabilizers are used in appropriate amounts to prevent aging and stabilize adhesives, drugs, and additives. Since the adhesive used in the present invention has a Tg of -71'C or lower, it has excellent drug transfer and absorption effects, but in order to further enhance these effects, a drug transfer and absorption enhancer is added. In addition, a surfactant is used in an appropriate amount to promote wetting of the skin by the drug. Furthermore, although the adhesive layer is mainly composed of (meth)acrylic acid alkyl ester polymer, in order to adjust its physical properties, other polymers (for example, rubber) may be added to this polymer in an amount of about 30% or less of the total polymer components. component) may be added.
3
裏打支持体層の支持体には、従来から知られ用いられて
いるあらゆる材料が包含される。特に、柔軟性や伸長性
を有するプラスチックフィルムやスポンジシート、柔軟
な織布、編布、不織布、またはそれらの積層体が好まし
い。例えば、支持体の素材には、ポリエチレンテレフタ
レート(PET)、エチレン−酢酸ビニル共重合体(E
VA)、ポリエチレン(特に、低密度ポリエチレン)、
ポリブタジェン、スチレン−ブタジェンまたはスチレン
−イソプレンを主体とするブロック共重合樹脂、ブタジ
ェン−スチレン−メタクリル酸メチル(MMA)共重合
樹脂、ナイロン、ポリウレタン、アルコキシアルキル(
メタ)アクリレート共重合体、ポリビニルアセクール、
可塑化された酢酸セルロースやエチルセルロースのよう
な繊維素誘導体、ポリアミノ酸類、水不溶化された水溶
性高分子(例えば、プルラン、ポリビニルピロリドン)
などが用いられる。支持体の厚さは、フィルムでは30
〜300μm1スポンジシートや織布、編布、不織布で
は、0,3〜3mmとされる。3. The support of the backing support layer includes all conventionally known and used materials. Particularly preferred are plastic films or sponge sheets having flexibility and extensibility, flexible woven fabrics, knitted fabrics, nonwoven fabrics, or laminates thereof. For example, materials for the support include polyethylene terephthalate (PET), ethylene-vinyl acetate copolymer (E
VA), polyethylene (especially low density polyethylene),
Polybutadiene, styrene-butadiene or styrene-isoprene-based block copolymer resins, butadiene-styrene-methyl methacrylate (MMA) copolymer resins, nylon, polyurethane, alkoxyalkyl (
meth)acrylate copolymer, polyvinyl acecool,
Cellulose derivatives such as plasticized cellulose acetate and ethylcellulose, polyamino acids, and water-insoluble water-soluble polymers (e.g., pullulan, polyvinylpyrrolidone)
etc. are used. The thickness of the support is 30 mm for the film.
~300 μm 1 For sponge sheets, woven fabrics, knitted fabrics, and non-woven fabrics, it is 0.3 to 3 mm.
4−
本発明の貼付剤は、裏打支持体層および粘着剤層を主体
とし、粘着剤層の表面に、剥離性保護紙またはシートを
付着させて提供される。剥離性保護紙またはシートには
滅菌処理が施されている。4- The adhesive patch of the present invention mainly includes a backing support layer and an adhesive layer, and is provided with a removable protective paper or sheet attached to the surface of the adhesive layer. The removable protective paper or sheet is sterilized.
本発明の貼付剤を得るには、例えば、以下の2つの方法
がある。There are, for example, the following two methods for obtaining the patch of the present invention.
(i)裏打支持体上に、粘着剤溶液(または、液状の粘
着剤)を塗布し乾燥して、粘着剤層を形成する。この場
合、この粘着剤層は、薬剤を含有していてもいなくても
よい。その場合、この粘着剤層に薬剤溶液が噴霧または
塗布される。再び粘着剤層を乾燥した後、粘着剤層の表
面に剥離性保護紙を付着させ、切断・包装して使用に供
される。但し、粘着剤溶液にあらかじめ薬剤が含有され
ている場合には、薬剤溶液の噴霧または塗布と粘着剤層
の再乾燥の工程は必要ではない。(i) An adhesive solution (or liquid adhesive) is applied onto the backing support and dried to form an adhesive layer. In this case, this adhesive layer may or may not contain a drug. In that case, a drug solution is sprayed or applied onto this adhesive layer. After drying the adhesive layer again, removable protective paper is attached to the surface of the adhesive layer, and the product is cut and packaged for use. However, if the adhesive solution contains a drug in advance, the steps of spraying or applying the drug solution and redrying the adhesive layer are not necessary.
(ii)剥離性保護紙の剥離性面上に、粘着剤溶液(ま
たは、液状の粘着剤)を塗布し乾燥して、粘着剤層を形
成する。この粘着剤層に薬剤溶液が噴霧または塗布され
る。再び粘着剤層を乾燥した後、15−
粘着剤層の表面に裏打支持体が積層され圧着されて、切
断・包装して使用に供される。但し、粘着剤溶液にあら
かじめ薬剤が含有されている場合には、薬剤溶液の噴霧
または塗布と粘着剤層の再乾燥の工程は必要ではない。(ii) An adhesive solution (or liquid adhesive) is applied on the releasable side of the releasable protective paper and dried to form an adhesive layer. A drug solution is sprayed or applied onto this adhesive layer. After drying the adhesive layer again, 15- a backing support is laminated and pressure-bonded on the surface of the adhesive layer, and the product is cut and packaged for use. However, if the adhesive solution contains a drug in advance, the steps of spraying or applying the drug solution and redrying the adhesive layer are not necessary.
このように得られた本発明の貼付剤において、粘着剤、
補強性繊維質充填剤および薬剤を含有する粘着剤層の保
持力値(H)および粘着力値(F)は、上述のように、
以下のa式およびb式の関係を有する:
H/F>0.3(秒/g) ・・・ aF>200g
・・・ bここで、式aは、
粘着剤層に凝集破壊が生じないことを、そして式すは、
粘着剤層が充分な粘着力を有することを示す。粘着剤層
の保持力値(H)および粘着力値(F)は、以下のよう
にして測定される:
(a)保持力値(H)
次の条件を用いたこと以外は、JIS−Z−0237(
保持力)に従って、粘着剤層の保持力値(H)を試験1
6−
した。In the patch of the present invention thus obtained, an adhesive,
As mentioned above, the retention force value (H) and adhesive force value (F) of the adhesive layer containing the reinforcing fibrous filler and the drug are as follows.
It has the following relationship of a formula and b formula: H/F>0.3 (sec/g) ... aF>200g
...bHere, formula a is
It is confirmed that cohesive failure does not occur in the adhesive layer, and the formula is
This shows that the adhesive layer has sufficient adhesive strength. The holding force value (H) and adhesion force value (F) of the adhesive layer are measured as follows: (a) Holding force value (H) JIS-Z except that the following conditions were used. -0237(
Test 1 The holding force value (H) of the adhesive layer was determined according to the holding force).
6- I did.
試料の大きさ二幅25±0.5mm
試験板への試料の貼付面積: 25mmX 25mm吊
り下げ荷重: tooo g
試験中の温度:30±1℃(加温)
測定値:荷重を加えてから、試料の貼付部分が“ズレ”
によって外れ、そして荷重が落下するまでの時間(秒〉
を保持力値(H)とする。但し、測定は、18000秒
(5時間)までとする。Sample size: 25 ± 0.5 mm in width Area of sample attached to test plate: 25 mm x 25 mm Suspended load: too g Temperature during test: 30 ± 1°C (heated) Measured value: After applying the load, The part where the sample is pasted is “misaligned”
time (seconds) until it comes off and the load falls.
is the holding force value (H). However, the measurement is limited to 18,000 seconds (5 hours).
(b)粘着力値(F)
次の条件を用いたこと以外は、JIS−Z−0237(
180度引きはがし法帖着力)に従って、粘着剤層の粘
着力値(F)を試験した。(b) Adhesive force value (F) JIS-Z-0237 (
The adhesive force value (F) of the adhesive layer was tested according to the 180 degree peeling method (adhesion force).
試料の大きさ:幅25±0.5■
試験中の温度:23±2℃(室温)
測定値:引きはがしがなされる荷重のg(ダラム)で表
示する。Size of sample: Width 25±0.5cm Temperature during test: 23±2°C (room temperature) Measured value: Displayed in g (duram) of the load at which peeling occurs.
上記保持力値(H)および粘着力値(F)は、それぞれ
、粘着剤層の凝集力および粘着力の基準となる。例えば
、この保持力値()()が低ければ、粘着17−
剤層は凝集破壊を起こし易くなり、粘着力値(F)が低
ければ、粘着剤は皮膚への貼付に必要かつ充分な粘着力
を有しなくなる。しかし、凝集力と粘着力とは互いに相
関関係にあるため、粘着剤層の保持力値(H)および粘
着力値(F)が−窓以上の値を示しても、それが必ずし
も実用に適するとは限らない。例えば、粘着剤層の保持
力値(H)が高い値を示しても、それがさらに高い粘着
力値(F)を有していれば、粘着剤は凝集破壊を起こす
。逆に、粘着剤層の保持力値(H)が低くても、粘着力
値(F)も同様に低ければ、粘着剤は凝集破壊を起こさ
ない。このようなことから、粘着剤層が一定の粘着力を
有するべく、上記の条件すを設定し、そして粘着剤が凝
集破壊を起こさない程度に粘着剤層の粘着性および凝集
性のバランスを保つべく、上記の条件aを設定した。こ
こで、上記の条件aおよびbの数値は、その値を境とし
て貼付剤の物性が著しく変わることを意味しない。しか
し、少なくとも上記の条件aおよびbに適合する貼付剤
は充分な粘着力を有し、かつ実用に耐えられないよう1
8−
な凝集破壊を起こさない(すなわち、粘着性と凝集性の
バランスに優れている)。The above-mentioned holding force value (H) and adhesive force value (F) serve as standards for the cohesive force and adhesive force of the adhesive layer, respectively. For example, if the cohesive force value () () is low, the adhesive layer is likely to cause cohesive failure, and if the adhesive force value (F) is low, the adhesive layer does not have the necessary and sufficient adhesiveness for application to the skin. no longer has power. However, cohesive force and adhesive force are correlated with each other, so even if the cohesive force value (H) and adhesive force value (F) of the adhesive layer show a value greater than -window, it is not necessarily suitable for practical use. Not necessarily. For example, even if the adhesive layer has a high coercive force value (H), if it has an even higher adhesive force value (F), the adhesive will cause cohesive failure. Conversely, even if the cohesive force value (H) of the adhesive layer is low, if the adhesive force value (F) is similarly low, the adhesive will not cause cohesive failure. For this reason, the above conditions are set so that the adhesive layer has a certain level of adhesive strength, and the balance between the adhesive and cohesive properties of the adhesive layer is maintained to the extent that the adhesive does not cause cohesive failure. In order to achieve this, the above condition a was set. Here, the numerical values of the above conditions a and b do not mean that the physical properties of the patch change significantly beyond these values. However, a patch that meets at least the above conditions a and b has sufficient adhesive strength and has a level of
8- Does not cause cohesive failure (i.e., has an excellent balance between adhesiveness and cohesiveness).
また、本発明の貼付剤を貼付けした後、剥離したときに
、粘着剤層に凝集破壊現象が生じるかどうかは、以下の
ように判定される。Further, whether or not a cohesive failure phenomenon occurs in the adhesive layer when the adhesive patch of the present invention is applied and then peeled off is determined as follows.
まず、前述のように貼付剤の粘着力値を測定する際に、
引き剥された試験面に、層状または部分的に粘着剤が残
留するかどうかを目視観察する。First, when measuring the adhesive strength of a patch as mentioned above,
Visually observe whether the adhesive remains on the peeled test surface in a layered or partial manner.
粘着剤の残留程度により、粘着剤層の凝集破壊の程度を
判定する。この方法にて、粘着剤層の凝集破壊が判別で
きないときは、次のようなチョーク粉試験を採用する。The degree of cohesive failure of the adhesive layer is determined based on the degree of residual adhesive. If cohesive failure of the adhesive layer cannot be determined by this method, the following chalk powder test is used.
すなわち、貼付剤を剥離した試験面上に、チョーク粉(
特に、着色チョーク粉)をふりかけ、粉の付着状況を観
察する。チョーク粉が試験面に著しく付着する場合には
、貼付剤の粘着剤層が凝集破壊を起こしたと認められる
。That is, chalk powder (
In particular, sprinkle colored chalk powder) and observe how the powder adheres. If chalk powder adheres significantly to the test surface, it is recognized that the adhesive layer of the patch has suffered cohesive failure.
(実施例) 以下に本発明の実施例について述べる。(Example) Examples of the present invention will be described below.
9−
アクリル酸−2−エチルヘキシル(主モノマー)184
.0重量部
メタクリル酸く補助モノマー)6.0重量部酢酸エチル
170M量部n−へキサン
10重量部上記処方を反応容器に仕込
み、N2気流中にて、60℃で8時間、70℃で8時間
、そして系の還流温度(約73℃)で8時間にわたり、
各反応物を重合させた。反応容器には、重合触媒として
、上記モノマーの全量の0.4モル%のアゾビスイソブ
チロニトリルを、8回に分けて18時間以内に加えた。9-2-ethylhexyl acrylate (main monomer) 184
.. 0 parts by weight methacrylic acid (auxiliary monomer) 6.0 parts by weight ethyl acetate 170M parts n-hexane
10 parts by weight of the above formulation was charged into a reaction vessel and heated in a N2 stream at 60°C for 8 hours, at 70°C for 8 hours, and at the reflux temperature of the system (approximately 73°C) for 8 hours.
Each reaction was allowed to polymerize. Azobisisobutyronitrile was added to the reaction vessel as a polymerization catalyst in an amount of 0.4 mol % based on the total amount of the monomers in 8 portions within 18 hours.
全反応時間24時間のうち、最後の6時間で攪拌および
還流を行い、触媒を充分に分解させて、反応を完結させ
た。重合反応後、粘稠なポリマー溶液が得られた。この
ポリマー溶液の極限粘度(30℃、トルエン溶媒系)は
1.684であった。得られたポリマーのガラス転移温
度(Tg)は、DSC4により、約53℃であった。Stirring and refluxing were performed during the last 6 hours of the total reaction time of 24 hours to fully decompose the catalyst and complete the reaction. After the polymerization reaction, a viscous polymer solution was obtained. The intrinsic viscosity of this polymer solution (30°C, toluene solvent system) was 1.684. The glass transition temperature (Tg) of the obtained polymer was about 53° C. by DSC4.
=20−
チルを加えて、40%酢酸エチル溶液とした。この溶液
100重量部あたり、Tg低下剤としてジオクチルフタ
レート16重量部を添加して、Tg(乾燥後)が約−8
3℃になるように粘着剤溶液を調製した。=20-tyl was added to make a 40% ethyl acetate solution. Per 100 parts by weight of this solution, 16 parts by weight of dioctyl phthalate was added as a Tg lowering agent, and the Tg (after drying) was approximately -8.
The adhesive solution was prepared to a temperature of 3°C.
1−3 2 ’の
(1−2)で得られた粘着剤溶液のポリマー成分100
重量部あたり、補強性繊維質充填剤として、スフ繊維(
平均直径;約12μm=平均繊維長約25mm)を8重
量部添加し、攪拌し混合することにより、粘着剤層形成
液を調製した。この溶液に薬剤を添加して、裏打支持体
上に塗布すれば、所望の貼付剤が得られる。1-3 Polymer component 100 of the adhesive solution obtained in 2' (1-2)
Per part by weight, as a reinforcing fibrous filler, Sufu fiber (
A pressure-sensitive adhesive layer forming liquid was prepared by adding 8 parts by weight of fibers having an average diameter of approximately 12 μm = average fiber length of approximately 25 mm, and stirring and mixing. By adding a drug to this solution and coating it on a backing support, the desired patch is obtained.
1−4 シートの およびその 試験(1−
3)で得られた粘着剤層形成液を、シート状の裏打支持
体(EVAフィルム;厚さ60μm)上に、乾燥後の厚
さが約55μm以上になるように流延し乾燥して、粘着
シートを作製した。この粘着シートから、約30mmX
30mmの試料2個を切り出し、各試料を人体胸部の
左右対称の位置に貼付した。24時間後に、貼付した試
料の状態を観察したところ、2(−
試料周辺への粘着剤の滲み出しはほとんど見られなかっ
た。また、この粘着シートは、剥離時に人体にやや痛み
を感じる程度の厚さの粘着剤層を有するにもかかられず
、試料の剥離後に、人体の皮膚に粘着剤が残留すること
も認められなかった。1-4 Sheet and its test (1-
The adhesive layer forming liquid obtained in 3) is cast onto a sheet-like backing support (EVA film; thickness 60 μm) so that the thickness after drying is about 55 μm or more, and dried. An adhesive sheet was produced. From this adhesive sheet, approximately 30mm
Two 30 mm samples were cut out, and each sample was pasted at symmetrical positions on the human chest. After 24 hours, we observed the condition of the attached sample and found that there was almost no oozing of the adhesive around the sample.Also, this adhesive sheet did not cause any pain to the human body when it was peeled off. Despite having a thick adhesive layer, no adhesive remained on the human skin after the sample was peeled off.
1−5 の 試
(1−2)で得られた粘着剤溶液を複数個用意し、各ポ
リマー成分100重量部あたり、薬剤としてインドメタ
シンを1重量部、2重量部、3重量部・・・と1重量部
間隔でそれぞれ添加し混合した。この混合物を、 P
ETフィルムのような透明フィルム上に流延し乾燥した
後、40℃で7日間放置して、顕微鏡などにより薬剤結
晶の析出状況を調べた。そして、薬剤結晶が析出しない
最大の薬剤添加部数を求めた。最大部数は22重量部で
あった。この数値を、薬剤最大含有量として表1に示す
。Prepare a plurality of adhesive solutions obtained in Test 1-5 (1-2), and add 1 part by weight, 2 parts by weight, 3 parts by weight, etc. of indomethacin as a drug per 100 parts by weight of each polymer component. Each was added at intervals of 1 part by weight and mixed. This mixture, P
After being cast onto a transparent film such as ET film and dried, it was left to stand at 40°C for 7 days, and the state of precipitation of drug crystals was examined using a microscope or the like. Then, the maximum number of parts of the drug to be added at which drug crystals would not precipitate was determined. The maximum number of parts was 22 parts by weight. This value is shown in Table 1 as the maximum drug content.
1−6 の 放 試験(1−2)で
得、られた粘着剤溶液のポリマー成分100重量部あた
り、(1−5)で求められた薬剤最大含有量のインドメ
タシンを加え、混合した。この混合物2
を、剥離性シート上に、厚さが70μmとなるように均
一に塗布し乾燥した後、さらに、PET (ポリエチレ
ンテレフタレート)フィルムを積層し圧着した。この積
層体から、直径6cmφの円形の試験片を切取った。こ
の試験片から剥離性シートを剥して、アセトン−水の混
合溶媒(重量比; 50: 5o)100 mlに、3
0℃にて6時間静置し浸せきさせた。Indomethacin in the maximum drug content determined in (1-5) was added and mixed per 100 parts by weight of the polymer component of the adhesive solution obtained in the release test (1-2) of 1-6. This mixture 2 was uniformly applied onto a releasable sheet to a thickness of 70 μm and dried, and then a PET (polyethylene terephthalate) film was further laminated and pressure-bonded. A circular test piece with a diameter of 6 cmφ was cut from this laminate. The releasable sheet was peeled off from this test piece, and 3
It was left to stand for 6 hours at 0°C to soak.
その後、試験片を混合溶媒から取り出し、液体クロマト
グラフィー法により、溶媒中に抽出された薬剤量を定量
した。試験片に含有されていると計算される薬剤量に対
する、抽出された薬剤量の割合(%〉を、粘着剤の薬剤
放出性の評価とした。抽出された薬剤量の割合は、71
%であった。これらの結果を表2に示す。Thereafter, the test piece was taken out from the mixed solvent, and the amount of drug extracted into the solvent was determined by liquid chromatography. The drug release property of the adhesive was evaluated as the ratio (%) of the extracted drug amount to the drug amount calculated to be contained in the test piece.The ratio of the extracted drug amount was 71
%Met. These results are shown in Table 2.
1−7の
(1−4)で得られた粘着シートから、幅25±0.5
mmの試料を切り出し、次の条件を用いたこと以外は、
JIS−Z−0237(保持力)に従って、粘着剤層の
保持力値(H)を試験した。但し、試料が伸び易い場合
には、試料の裏打支持体側にPETテープを張り付は2
3−
て、伸び易さを防止しr裏面補強)、試験に供した。From the adhesive sheet obtained in 1-7 (1-4), the width is 25 ± 0.5
Except that a mm sample was cut and the following conditions were used.
The holding force value (H) of the adhesive layer was tested according to JIS-Z-0237 (holding force). However, if the sample is easy to stretch, apply PET tape to the backing support side of the sample.
3- (reinforced back surface to prevent easy stretching) and subjected to test.
試験板への試料の貼付面積: 25mmX 25mm吊
り下げ荷重: 1000 g
試験中の温度=30±1℃(加温)
測定値:荷重を加えてから、試料の貼付部分が“ズレ”
によって外れ、そして荷重が落下するまでの時間(秒)
を保持力値(H)とする。保持力値は964(秒)であ
った。Area of the sample pasted on the test plate: 25mm x 25mm Hanging load: 1000 g Temperature during test = 30±1℃ (heated) Measured value: After applying the load, the part of the sample pasted “slips”
The time it takes for the load to fall and the load to fall (seconds)
is the holding force value (H). The holding force value was 964 (seconds).
1−8 却の 試験
<1−4)で得られた粘着シートから、幅25±0.5
mmの試料を切り出し、次の条件を用いたこと以外は、
JIS−Z−0237(180度引きはがし法帖着力)
に従って、粘着剤層の粘着力値(F)を試験した。但し
、必要に応じて、(1−7)と同様に試料に裏面補強を
施した。1-8 Test <1-4) Width 25±0.5
Except that a mm sample was cut and the following conditions were used.
JIS-Z-0237 (180 degree peeling strength)
The adhesive force value (F) of the adhesive layer was tested according to the following. However, if necessary, the back surface of the sample was reinforced in the same manner as in (1-7).
試験中の温度=23±2℃(室温)
測定値:引きはがしがなされる荷重のg(ダラム)で表
示する。粘着力値は、287 (g/25mm)であっ
た。Temperature during test = 23±2°C (room temperature) Measured value: Displayed in g (duram) of the load at which peeling occurs. The adhesive strength value was 287 (g/25mm).
(1−7)の保持力試験およびこの粘着力試験でそれ2
4−
ぞれ得られた保持力値(H)および粘着力値(F)に基
づいて、H/Fの値を算出した。H/Fは3.36であ
った。また、この粘着力試験で引きはがしがなされた後
の粘着剤の凝集破壊状況について目視観察したところ、
粘着剤の凝集破壊は認められなかった。これらの結果を
表3に示す。(1-7) holding force test and this adhesive force test showed that it was 2.
4- The value of H/F was calculated based on the holding force value (H) and adhesive force value (F) obtained respectively. H/F was 3.36. In addition, when we visually observed the cohesive failure status of the adhesive after it was peeled off in this adhesive force test, we found that
No cohesive failure of the adhesive was observed. These results are shown in Table 3.
里較側ユニ
実施例1の(1−1)および(1−2)と同様にして、
ポリマー溶液を合成しそして粘着剤溶液を調製した。In the same manner as (1-1) and (1-2) in Example 1 on the comparison side,
A polymer solution was synthesized and an adhesive solution was prepared.
この粘着剤溶液に補強性繊維質充填剤を加えなかったこ
と以外は、実施例1の(1−3)および(1−4)と同
様にして、粘着剤層形成液を調製しそして粘着シートを
作製した。この粘着シートに対し、実施例1の(1−4
)と同様の方法により、補強性試験を行った。その結果
、人体の貼付箇所にて、試料周辺への粘着剤の滲み出し
幅は、平均して3+nm以上あった。また、試料の剥離
後に、粘着剤層の凝集破壊により、人体の皮膚に粘着剤
が残留し、汚れとなっていた。An adhesive layer forming solution was prepared in the same manner as in Example 1 (1-3) and (1-4), except that no reinforcing fibrous filler was added to this adhesive solution, and an adhesive sheet was prepared. was created. For this adhesive sheet, (1-4
) A reinforcing test was conducted using the same method. As a result, the width of the adhesive exuding around the sample at the attachment point on the human body was 3+ nm or more on average. Further, after the sample was peeled off, the adhesive remained on the human skin due to cohesive failure of the adhesive layer, resulting in stains.
里較男」1
25一
実施例1の(1−1)と同様にして、ポリマー溶液を合
成した。このポリマー溶液(7g低下剤および補強性繊
維質充填剤が加えられていない二Tgは約−53℃)に
ついて、実施例1の(1−5)と同様の方法により、粘
着剤の薬剤含有試験を行った。薬剤結晶が析出しない最
大部数は10重量部であった。この数値を、薬剤最大含
有量として表1に示す。A polymer solution was synthesized in the same manner as in Example 1 (1-1). This polymer solution (with no 7g lowering agent and reinforcing fibrous filler added, Tg is approximately -53°C) was tested for drug content in the adhesive by the same method as in Example 1 (1-5). I did it. The maximum number of parts at which drug crystals did not precipitate was 10 parts by weight. This value is shown in Table 1 as the maximum drug content.
里較Iユづ
実施例1と同様にして、ポリマー溶液を合成した。この
ポリマー溶液について、実施例1の(1−6〉と同様の
方法により、比較例1−2で算出された薬剤最大含有量
を参照して、粘着剤の薬剤放出性試験を行った。抽出さ
れた薬剤量の割合は49%であった。その結果を表2に
示す。A polymer solution was synthesized in the same manner as in Example 1. Regarding this polymer solution, a drug release property test for the adhesive was conducted using the same method as in Example 1 (1-6), with reference to the maximum drug content calculated in Comparative Example 1-2.Extraction The percentage of drug amount administered was 49%.The results are shown in Table 2.
迄較男ユゴ
実施例1の(1−1)および(1−2)と同様にして、
ポリマー溶液を合成しそして粘着剤溶液を調製した。Until then, in the same manner as (1-1) and (1-2) of Example 1,
A polymer solution was synthesized and an adhesive solution was prepared.
この粘着剤溶液に補強性繊維質充填剤を加えなかったこ
と以外は、実施例1の(1−3)および(1−4)と同
様にして、粘着剤層形成液を調製しそして粘着6−
シートを作製した。この粘着シートに対し、実施例1の
(1−7)および(1−8)と同様の方法により、それ
ぞれ粘着剤層の保持力値(H)および粘着力値(F)を
測定しモしてH/Fの値を算出した。保持力値は75(
秒)、粘着力値は325〜780 (g/25mm)で
あり、モしてH/Fは0.23であった。粘着力値にバ
ラツキが認められるのは、粘着剤層の凝集破壊傾向のた
めである。また、この粘着力試験で引きはがしがなされ
た後の粘着剤の凝集破壊状況について目視観察したとこ
ろ、僅かではあるが粘着剤の凝集破壊が認められた。こ
れらの結果を表3に示す。An adhesive layer forming solution was prepared in the same manner as in Example 1 (1-3) and (1-4), except that no reinforcing fibrous filler was added to the adhesive solution, and the adhesive layer forming solution was − A sheet was produced. For this adhesive sheet, the holding force value (H) and adhesive force value (F) of the adhesive layer were measured using the same methods as in Example 1 (1-7) and (1-8), respectively. The value of H/F was calculated. The holding force value is 75 (
The adhesive force value was 325 to 780 (g/25 mm), and the H/F was 0.23. The reason for the observed variation in adhesive force values is the tendency for cohesive failure of the adhesive layer. Further, when the cohesive failure state of the adhesive was visually observed after being peeled off in this adhesive strength test, it was observed that the adhesive had a slight cohesive failure. These results are shown in Table 3.
アクリル酸−n−オクチル(生モノマー−1)92.0
重量部
アクリル酸−〇−ノニル(主モノマー−2)990重量
部
アクリル酸(補助モノマー) 5.0fiffi部
酢酸エチル 140重量部n−へキ
サン 20重量部27
上記処方を反応容器に仕込み、N2気流中にて、60℃
で8時間、70℃で8時間、そして系の還流温度(約7
4’C)で8時間にわたり、各反応物を重合させた。反
応容器には、重合触媒として、上記モノマーの全量の0
.3モル%の過酸化ラウロイルを、8回に分けて18時
間以内に加えた。全反応時間24時間のうち、最後の6
時間で攪拌および還流を行い、触媒を充分に分解させて
、反応を完結させた。n-octyl acrylate (raw monomer-1) 92.0
Parts by weight -〇-nonyl acrylate (main monomer 2) 990 parts by weight Acrylic acid (auxiliary monomer) 5.0 parts by weight Ethyl acetate 140 parts by weight n-hexane 20 parts by weight 27 The above formulation was charged into a reaction vessel, and N2 gas flow was applied. Inside, 60℃
for 8 hours at 70°C, and at the reflux temperature of the system (approximately 7
Each reaction was polymerized for 8 hours at 4'C). In the reaction vessel, 0 of the total amount of the above monomers was added as a polymerization catalyst.
.. 3 mole % lauroyl peroxide was added in 8 portions within 18 hours. Of the total reaction time of 24 hours, the last 6
Stirring and refluxing were performed for several hours to fully decompose the catalyst and complete the reaction.
重合反応後、粘稠なポリマー溶液が得られた。このポリ
マー溶液の極限粘度(トルエン溶媒系)は1、711で
あり、そしてTgは約−62℃であった。After the polymerization reaction, a viscous polymer solution was obtained. The intrinsic viscosity of this polymer solution (toluene solvent system) was 1,711 and the Tg was about -62°C.
2−2 昂r°の一0′
(2−1)で得られたポリマー溶液に、追加の酢酸エチ
ルを加えて、40%酢酸エチル溶液とした。この溶液1
00重量部あたり、7g低下剤としてオリーブ油18重
量部を添加して、Tg(乾燥後)が−88℃になるよう
に粘着剤溶液を調製した。2-2 Additional ethyl acetate was added to the polymer solution obtained in 2-1 to obtain a 40% ethyl acetate solution. This solution 1
An adhesive solution was prepared by adding 18 parts by weight of olive oil as a 7g reducing agent per 00 parts by weight so that the Tg (after drying) would be -88°C.
2−3 作 〉 の−1.′
(2−2)で得られた粘着剤溶液のポリマー成分100
重量部あたり、補強性繊維質充填剤として、表面28−
がポラン処理されたガラス短繊維(平均直径;8μm1
平均繊維長;30μm)を(2重量部添加し、攪拌し
混合することにより、粘着剤層形成液を調製した。この
溶液に薬剤を添加して、裏打支持体上に塗布すれば、所
望の貼付剤が得られる。2-3 -1. ' Polymer component 100 of the adhesive solution obtained in (2-2)
Per part by weight, as a reinforcing fibrous filler, short glass fibers (average diameter: 8 μm
A pressure-sensitive adhesive layer forming solution was prepared by adding 2 parts by weight of (average fiber length: 30 μm) and stirring and mixing. When the drug was added to this solution and coated on the backing support, the desired layer was formed. A patch is obtained.
2−4 シートの およびその 強 試験(2−
3)で得られた粘着剤層形成液を用いたこと以外は、実
施例1と同様の方法により、粘着シートを作製し、その
補強性試験を行った。その結果、試料周辺への粘着剤の
滲み出しはほとんど見られなかった。また、この粘着シ
ートは、剥離時に人体にやや痛みを感じる程度の厚さ(
約55μm以上)の粘着剤層を有するにもかかられす、
試料の剥離後に、人体の皮膚に粘着剤が残留することも
認められなかった。2-4 Sheet and its strength test (2-
A pressure-sensitive adhesive sheet was prepared in the same manner as in Example 1, except that the pressure-sensitive adhesive layer forming liquid obtained in step 3) was used, and its reinforcing property test was conducted. As a result, almost no oozing of the adhesive around the sample was observed. In addition, this adhesive sheet is thick enough to cause some pain to the human body when peeled off (
It also applies to having an adhesive layer of about 55 μm or more).
No adhesive was observed to remain on the human skin after the sample was peeled off.
2−5の
(2−2)で得られた粘着剤溶液を用いたこと以外は、
実施例1と同様の方法により、薬剤結晶が析出しない最
大の部数を求めた。最大部数は24重量部であった。こ
の数値を、薬剤最大含有量として表1=29−
に示す。Except for using the adhesive solution obtained in 2-5 (2-2),
By the same method as in Example 1, the maximum number of copies at which drug crystals would not precipitate was determined. The maximum number of parts was 24 parts by weight. This value is shown in Table 1 = 29- as the maximum drug content.
2−6の
(2−2)で得られた粘着剤溶液に対し、(2−5)で
算出された薬剤最大含有量のインドメタシンを加えたこ
と以外は、実施例1と同様の方法により、粘着剤の薬剤
放出性を評価した。抽出された薬剤量の割合は、78%
であった。これらの結果を表2に示す。In the same manner as in Example 1, except that indomethacin with the maximum drug content calculated in (2-5) was added to the adhesive solution obtained in (2-2) of 2-6, The drug release properties of the adhesive were evaluated. The proportion of extracted drug amount is 78%
Met. These results are shown in Table 2.
2−7 − の ・(2−4)で得
られた粘着シートを用いたこと以外は、実施例1と同様
にして、粘着剤層の保持力値(H)を測定した。保持力
値は1196 (秒)であった。2-7 - The holding force value (H) of the adhesive layer was measured in the same manner as in Example 1, except that the adhesive sheet obtained in (2-4) was used. The holding force value was 1196 (seconds).
2−8 印の 試
(2−4)で得られた粘着シートを用いたこと以外は、
実施例1と同様にして、粘着剤層の粘着力値(H)を測
定した。粘着力値は335 (g/25mm)であった
。Except for using the adhesive sheet obtained in test (2-4) marked 2-8.
In the same manner as in Example 1, the adhesive force value (H) of the adhesive layer was measured. The adhesive force value was 335 (g/25mm).
(2−7)の保持力試験およびこの粘着力試験でそれぞ
れ得られた保持力値(H)および粘着力値(F)に基づ
いて、H/Fの値を算出した。H/ Fは3.57であ
った。また、この粘着力試験で引きはがしが0
なされた後の粘着剤の凝集破壊状況について目視観察し
たところ、粘着剤の凝集破壊は認められなかった。これ
らの結果を表3に示す。The value of H/F was calculated based on the holding force value (H) and adhesive force value (F) obtained in the holding force test (2-7) and this adhesive force test, respectively. H/F was 3.57. Further, when the cohesive failure state of the adhesive was visually observed after 0 peeling was performed in this adhesive strength test, no cohesive failure of the adhesive was observed. These results are shown in Table 3.
里較泗ユニ
実施例2の(2−1)および(2−2)と同様にして、
ポリマー溶液を合成しそして粘着剤溶液を調製した。Similarly to (2-1) and (2-2) of Example 2,
A polymer solution was synthesized and an adhesive solution was prepared.
この粘着剤溶液に補強性繊維質充填剤を加えなかったこ
と以外は、実施例2の(2−3)および(2−4)と同
様にして、粘着剤層形成液を調製しそして粘着シートを
作製した。この粘着シートに対し、実施例1の(1−4
)と同様の方法により、補強性試験を行った。その結果
、人体の貼付箇所にて、試料周辺に粘着剤が激しく滲み
出した。また、試料の剥離後に、粘着剤層の凝集破壊に
より、人体の皮膚に粘着剤が残留し、汚れとなっていた
。An adhesive layer forming solution was prepared in the same manner as in Example 2 (2-3) and (2-4), except that no reinforcing fibrous filler was added to this adhesive solution, and an adhesive sheet was prepared. was created. For this adhesive sheet, (1-4
) A reinforcing test was conducted using the same method. As a result, the adhesive oozed out violently around the sample at the point where it was applied on the human body. Further, after the sample was peeled off, the adhesive remained on the human skin due to cohesive failure of the adhesive layer, resulting in stains.
塩較泗ユ」
実施例2の(2−1)と同様にして、ポリマー溶液を合
成した。このポリマー溶液(Tg低下剤および補強性繊
維質充填剤が加えられていない:Tgは約62℃)につ
いて、実施例1の(1−5)と同様の方法に31−
より、粘着剤の薬剤含有試験を行った。薬剤結晶が析出
しない最大部数は12重量部であった。この数値を、薬
剤最大含有量として、表1に示す。A polymer solution was synthesized in the same manner as in Example 2 (2-1). For this polymer solution (no Tg lowering agent and reinforcing fibrous filler added: Tg is about 62°C), the adhesive agent was prepared using the same method as Example 1 (1-5). A content test was conducted. The maximum number of parts at which drug crystals did not precipitate was 12 parts by weight. This value is shown in Table 1 as the maximum drug content.
よ較男1づ
実施例2の(2−1)と同様にして、ポリマー溶液を合
成した。このポリマー溶液について、実施例1の(1−
6)と同様の方法により、比較例2−2で算出された薬
剤最大含有量を参照して、粘着剤の薬剤放出性試験を行
った。抽出された薬剤量の割合は52%であった。その
結果を表2に示す。A polymer solution was synthesized in the same manner as in Example 2 (2-1). Regarding this polymer solution, (1-
A drug release property test of the adhesive was conducted in the same manner as in 6) with reference to the maximum drug content calculated in Comparative Example 2-2. The percentage of extracted drug amount was 52%. The results are shown in Table 2.
止藍Iユニ
実施例2の(2−1)および(2−2)と同様にして、
ポリマー溶液を合成しそして粘着剤溶液を調製した。In the same manner as (2-1) and (2-2) of Indigo I Uni Example 2,
A polymer solution was synthesized and an adhesive solution was prepared.
この粘着剤溶液に補強性繊維質充填剤を加えなかったこ
と以外は、実施例2の(2−3)および(2−4)と同
様にして、粘着剤層形成液を調製しそして粘着シートを
作製した。この粘着シートに対し、実施例1の(1−7
)および(1−8)と同様の方法により、それぞれ粘着
剤層の保持力値(H)および粘着力値(F)を測定しモ
してH/Fの値を算出した。保持力値32
は76(秒)、粘着力値は364〜1040 (g/2
5mm)であり、モしてH/Fは0.21であった。粘
着力値にノくラツキが認められるのは、粘着剤層の凝集
破壊傾向のためである。また、この粘着力試験で引きζ
ま力くしがなされた後の粘着剤の凝集破壊状況につl、
Xて目視観察したところ、僅かではあるが粘着剤の凝集
破壊が認められた。これらの結果を表3に示す。An adhesive layer forming solution was prepared in the same manner as in Example 2 (2-3) and (2-4), except that no reinforcing fibrous filler was added to this adhesive solution, and an adhesive sheet was prepared. was created. For this adhesive sheet, (1-7
) and (1-8), the holding force value (H) and adhesive force value (F) of the adhesive layer were measured, respectively, and the value of H/F was calculated. Holding force value 32 is 76 (seconds), adhesive force value is 364-1040 (g/2
5 mm), and H/F was 0.21. The reason why the adhesive strength value varies is due to the tendency of the adhesive layer to fail cohesively. In addition, in this adhesive strength test,
Regarding the cohesive failure status of the adhesive after being combed,
When visually observed using X, cohesive failure of the adhesive was observed, albeit slightly. These results are shown in Table 3.
アクリル酸−n−オクチル(生モノマー−1)92重量
部
メタクリル酸−n−デシル(生モノマー−2)106重
量部
へ牛サンジオールジメタクリレート(補助モノマー)
0.01重量部酢酸エチ
ル 100重量部n−ヘキサン
20重量部上記処方を反応容器に
仕込み、N2気流中(こて、60′Cテ8時間、70℃
で8時間、そして系の還流温度(約75℃)で8時間に
わたり、各反応物を重合33
させた。反応容器には、重合触媒として、上記モノマー
の全量の0.25モル%の過酸化ベンゾイルを、98回
に分けて18時間にわたり加えた。全反応時間24時間
のうち、最後の6時間で攪拌および還流を行い、触媒を
充分に分解させて、反応を完結させた。重合反応後、粘
稠なポリマー溶液が得られた。To 92 parts by weight of n-octyl acrylate (raw monomer-1) and 106 parts by weight of n-decyl methacrylate (raw monomer-2), add bovine sane diol dimethacrylate (auxiliary monomer).
0.01 parts by weight Ethyl acetate 100 parts by weight n-hexane
20 parts by weight of the above formulation was charged into a reaction vessel and heated at 70°C for 8 hours at 60'C in a N2 stream (trowel, 60'C).
Each reaction was polymerized for 8 hours at 33° C. and at the reflux temperature of the system (approximately 75° C.) for 8 hours. Benzoyl peroxide was added to the reaction vessel as a polymerization catalyst in an amount of 0.25 mol % based on the total amount of the monomers in 98 portions over 18 hours. Stirring and refluxing were performed during the last 6 hours of the total reaction time of 24 hours to fully decompose the catalyst and complete the reaction. After the polymerization reaction, a viscous polymer solution was obtained.
このポリマー溶液の極限粘度(トルエン溶媒系)は1.
797であり、そしてTgは約−67℃であった。The intrinsic viscosity of this polymer solution (toluene solvent system) is 1.
797, and the Tg was approximately -67°C.
3−2 ” ’ の−,1
<3−1)で得られたポリマー溶液に、追加の酢酸エチ
ルを加えて、40%酢酸エチル溶液とした。この溶液1
00重量部あたり、Tg低下剤としてセバシン酸ジオク
チル12重量部を添加して、Tg(乾燥後)が−85℃
になるように粘着剤溶液を調製した。Additional ethyl acetate was added to the polymer solution obtained in 3-2 '''' -, 1 <3-1) to obtain a 40% ethyl acetate solution.This solution 1
00 parts by weight, 12 parts by weight of dioctyl sebacate was added as a Tg lowering agent, and the Tg (after drying) was -85°C.
An adhesive solution was prepared as follows.
3−3 ” の−。′
(3−2)で得られた粘着剤溶液のポリマー成分100
重量部あたり、補強性繊維質充填剤として、ポリアクリ
ロニトリル短繊維(平均直径;15μm、平均繊維長;
15mm)を18重量部添加し、攪拌し混合すること
により、粘着剤層形成液を調製した。こ34
の溶液に薬剤を添加して、裏打支持体上(こ塗布すれば
、所望の貼付剤が得られる。3-3 "-.' Polymer component 100 of the adhesive solution obtained in (3-2)
Per weight part, polyacrylonitrile short fibers (average diameter: 15 μm, average fiber length;
A pressure-sensitive adhesive layer forming liquid was prepared by adding 18 parts by weight of 15 mm) and stirring and mixing. By adding a drug to this solution and coating it on the backing support, the desired patch can be obtained.
3−4 シートの およびその 試(3−3
)で得られた粘着剤層形成液を用し)たこと以外は、実
施例1と同様の方法により、粘着シートを作製し、その
補強性試験を行った。その結果、貼付剤のずれや粘着剤
の試料周辺への滲み出しくま見られなかった。また、試
料の剥離後(こ、人体の皮膚に粘着剤が残留することも
認められな力)つた。3-4 Sheet and its trial (3-3
A pressure-sensitive adhesive sheet was prepared in the same manner as in Example 1, except that the pressure-sensitive adhesive layer forming liquid obtained in step 1) was used, and its reinforcing property test was conducted. As a result, no deviation of the patch or oozing of the adhesive around the sample was observed. In addition, after the sample was peeled off (with a force that would not allow adhesive to remain on human skin).
3−5 卵の′却 試験
(3−2)で得られた粘着剤溶液を用L)たこと以外(
ま、実施例1と同様の方法により、薬剤結晶力く析出し
ない最大の部数を求めた。最大部数は21重量部であっ
た。この数値を、薬剤最大含有量として表1に示す。3-5 Except for using the adhesive solution obtained in test (3-2)
By the same method as in Example 1, the maximum number of copies without crystallization of the drug was determined. The maximum number of parts was 21 parts by weight. This value is shown in Table 1 as the maximum drug content.
3−6 の′ )
(3−2)で得られた粘着剤溶液に対し、(3−5)で
算出された薬剤最大含有量のインドメタシンを力Oえた
こと以外は、実施例1と同様の方法(こより、才占着剤
の薬剤放出性を評価した。抽出された薬¥ILffi−
35=
の割合は、74%であった。これらの結果を表2に示す
。3-6') The same procedure as in Example 1 was carried out except that indomethacin with the maximum drug content calculated in (3-5) was added to the adhesive solution obtained in (3-2). Method (From this, we evaluated the drug release properties of the drug-fixing agent. Extracted drug\ILffi-
The proportion of 35= was 74%. These results are shown in Table 2.
3−7 の0
(3−4)で得られた粘着シートを用いたこと以外は、
実施例1と同様にして、粘着剤層の保持力値(H)を測
定した。保持力値は1057(秒)であった。3-7 No. 0 (3-4) Except for using the adhesive sheet,
In the same manner as in Example 1, the holding force value (H) of the adhesive layer was measured. The holding force value was 1057 (seconds).
3−8 着印の 着 試験
(3−4)で得られた粘着シートを用いたこと以外は、
実施例1と同様にして、粘着剤層の粘着力値(H)を測
定した。粘着力値は341 (g/25mm)であった
。3-8 Imprinting Other than using the adhesive sheet obtained in test (3-4),
In the same manner as in Example 1, the adhesive force value (H) of the adhesive layer was measured. The adhesive force value was 341 (g/25mm).
(3−7)の保持力試験およびこの粘着力試験でそれぞ
れ得られた保持力値(H)および粘着力値(F)に基づ
いて、H/Fの値を算出した。H/Fは3.10であっ
た。また、この粘着力試験で引きはがしがなされた後の
粘着剤の凝集破壊状況について目視観察したところ、粘
着剤の凝集破壊は認められなかった。これらの結果を表
3に示す。The value of H/F was calculated based on the holding force value (H) and adhesive force value (F) obtained in the holding force test (3-7) and this adhesive force test, respectively. H/F was 3.10. In addition, when the cohesive failure of the adhesive was visually observed after being peeled off in this adhesive strength test, no cohesive failure of the adhesive was observed. These results are shown in Table 3.
天笠11づ
実施例3の(3−1)および(3−2)と同様にして、
ポリマー溶液を合或しそして粘着剤溶液を調製した。Amagasa 11 In the same manner as (3-1) and (3-2) of Example 3,
The polymer solutions were combined and the adhesive solution was prepared.
−3に
の粘着剤溶液に補強性繊維質充填剤を加えなかったこと
以外は、実施例3の(3−3)および(3−4)と同様
にして、粘着剤層形成液を調製しそして粘着シートを作
製した。この粘着シートに対し、実施例1の(L−4)
と同様の方法により、補強性試験を行った。その結果、
人体の貼付箇所にて、粘着剤の凝集力不足により、貼付
剤のずれや粘着剤の試料周辺への滲み出しが見られた。An adhesive layer forming solution was prepared in the same manner as in (3-3) and (3-4) of Example 3, except that no reinforcing fibrous filler was added to the adhesive solution in -3. Then, an adhesive sheet was produced. For this adhesive sheet, (L-4) of Example 1
A reinforcing test was conducted using the same method as above. the result,
At the point where it was applied on the human body, due to insufficient cohesive force of the adhesive, slippage of the adhesive and oozing of the adhesive around the sample were observed.
試料の剥離後に、人体の皮膚に粘着剤が残留し、汚れと
なっていた。After the sample was peeled off, the adhesive remained on the human skin, resulting in stains.
塩較ヱ1づ
実施例3の(3−1)と同様にして、ポリマー溶液を合
成した。このポリマー溶液(Tg低下剤および補強性繊
維質充填剤が加えられていない:Tgは約67℃)につ
いて、実施例1の(1−5)と同様の方法により、粘着
剤の薬剤含有試験を行った。薬剤結晶が析出しない最大
部数は14重量部であった。この数値を、薬剤最大含有
量として表1に示す。Salt Comparison 1 A polymer solution was synthesized in the same manner as in Example 3 (3-1). For this polymer solution (no Tg lowering agent and reinforcing fibrous filler added: Tg is approximately 67°C), a drug content test for the adhesive was conducted in the same manner as in Example 1 (1-5). went. The maximum number of parts at which drug crystals did not precipitate was 14 parts by weight. This value is shown in Table 1 as the maximum drug content.
里較ヨ1ユ
実施例3の(3−1)と同様にして、ポリマー溶液を合
成した。このポリマー溶液について、実施例17
の(1−6)と同様の方法により、比較例3−2で算出
された薬剤最大含有量を参照して、粘着剤の薬剤放出性
試験を行った。抽出された薬剤量の割合は58%であっ
た。その結果を表2に示す。A polymer solution was synthesized in the same manner as in Example 3 (3-1). Regarding this polymer solution, a drug release property test of the adhesive was conducted using the same method as in Example 17 (1-6) with reference to the maximum drug content calculated in Comparative Example 3-2. The percentage of extracted drug amount was 58%. The results are shown in Table 2.
塩較男1ユ
実施例3の(3−1)および(3−2)と同様にして、
ポリマー溶液を合成しそして粘着剤溶液を調製した。Similarly to (3-1) and (3-2) of Example 3,
A polymer solution was synthesized and an adhesive solution was prepared.
この粘着剤溶液に補強性繊維質充填剤を加えなかったこ
と以外は、実施例3の(3−3)および(3−4)と同
様にして、粘着剤層形成液を調製しそして粘着シートを
作製した。この粘着シートに対し、実施例1の(1−7
)および(1−8)と同様の方法により、それぞれ粘着
剤層の保持力値(H)および粘着力値(F)を測定しモ
してH/Fの値を算出した。保持力値は102(秒)、
粘着力値は360〜715 (g/25mm)であり、
モしてH/Fは0.28であった。粘着力値にバラツキ
が認められるのは、粘着剤層の凝集破壊傾向のためであ
る。また、この粘着力試験で引きはがしがなされた後の
粘着剤の凝集破壊状況について目視観察したところ、極
めて僅かではあるものの、38
粘着剤の凝集破壊が認められた。An adhesive layer forming solution was prepared in the same manner as in Example 3 (3-3) and (3-4), except that no reinforcing fibrous filler was added to this adhesive solution, and a pressure-sensitive adhesive sheet was prepared. was created. For this adhesive sheet, (1-7
) and (1-8), the holding force value (H) and adhesive force value (F) of the adhesive layer were measured, respectively, and the value of H/F was calculated. Holding force value is 102 (seconds),
The adhesive strength value is 360 to 715 (g/25mm),
The H/F was 0.28. The reason for the observed variation in adhesive force values is the tendency for cohesive failure of the adhesive layer. In addition, when the cohesive failure state of the adhesive was visually observed after being peeled off in this adhesive force test, cohesive failure of the 38 adhesive was observed, although it was extremely slight.
これらの結果を 表3に示す。These results It is shown in Table 3.
(以下余白)
39−
表1
表2
表3
0
実施例および比較例から明らかなように、本発明の貼付
剤は、粘着剤層に補強性繊維質充填剤を含有するため、
粘着性と凝集性のバランスに優れている。このことは、
貼付剤の粘着力値(F)が2゜0g以上であると共に、
保持力値(H)と粘着力値(F)の比:H/F>OJ秒
/gであることから、証明される。従って、この貼付剤
を人体に貼付しても粘着剤の滲み出しが少ない。しかも
、貼付剤の剥離後に、人体の皮膚に粘着剤が残留するこ
ともない。本発明の貼付剤は、さらに、ガラス転移温度
(Tg)が−71’C以下の粘着剤で粘着剤層が構成さ
れるため、多量の薬剤が粘着剤層に含有され得るうえに
、薬剤の放出性に優れている。(The following is a blank space) 39- Table 1 Table 2 Table 3 0 As is clear from the Examples and Comparative Examples, since the patch of the present invention contains a reinforcing fibrous filler in the adhesive layer,
Excellent balance of adhesiveness and cohesiveness. This means that
The adhesive force value (F) of the patch is 2°0g or more, and
This is proven because the ratio of the holding force value (H) to the adhesive force value (F): H/F>OJ seconds/g. Therefore, even when this patch is applied to the human body, there is little oozing of the adhesive. Moreover, no adhesive remains on the human skin after the patch is peeled off. Further, in the adhesive patch of the present invention, since the adhesive layer is composed of an adhesive having a glass transition temperature (Tg) of -71'C or lower, a large amount of drug can be contained in the adhesive layer, and the drug Excellent release properties.
粘着剤層に補強性繊維質充填剤を含有しない貼付剤は、
粘着性と凝集性のバランスが悪く、その粘着力は200
g以上であるものの、保持力値(H)と粘着力値(F)
の比: H/F≦ 0.3秒/gである。A patch that does not contain reinforcing fibrous filler in the adhesive layer is
The balance between stickiness and cohesiveness is poor, and the stickiness is 200.
Although it is more than g, the holding force value (H) and adhesive force value (F)
Ratio: H/F≦0.3 seconds/g.
従って、この貼付剤を人体に貼付すると、その周辺部に
粘着剤が滲み出し、貼付剤が著しくずれる。Therefore, when this patch is applied to a human body, the adhesive oozes out around the patch, causing the patch to shift significantly.
また、貼付剤の剥離後には、人体の皮膚に粘着剤1
が残留し、汚れとなる。ガラス転移温度(Tg)が−7
1℃を越える粘着剤で粘着剤層が構成される貼付剤は、
粘着剤層に多量の薬剤を含有し得ない。しかも、粘着剤
層からの薬剤の放出性にも劣る。Further, after the patch is peeled off, the adhesive 1 remains on the human skin and becomes a stain. Glass transition temperature (Tg) is -7
For patches whose adhesive layer is made of adhesive with a temperature exceeding 1℃,
The adhesive layer cannot contain a large amount of drug. Furthermore, the release properties of the drug from the adhesive layer are also poor.
(発明の効果)
本発明の貼付剤は、このように、粘着剤として、ガラス
転移温度(Tg)が−71℃以下である新規なアクリル
酸エステル系ポリマーを用いているため、粘着剤層に多
量の薬剤が溶解され、そして薬剤の放出性も高い。しか
も、この貼付剤は、粘着剤層に補強性繊維質充填剤を含
有するため、粘着性と凝集性のバランスに優れている。(Effects of the Invention) As described above, the adhesive patch of the present invention uses a novel acrylic acid ester polymer with a glass transition temperature (Tg) of -71°C or less as an adhesive, so the adhesive layer is A large amount of drug is dissolved and drug release is also high. Moreover, this adhesive patch contains a reinforcing fibrous filler in the adhesive layer, so it has an excellent balance between adhesiveness and cohesiveness.
従って、この貼付剤を用いれば、薬効が高まるために薬
剤の利用効率が増大する。1つの貼付剤に多量の薬剤が
含有され得るため、経済的でもある。さらに、この貼付
剤を人体の皮膚に貼付しても、粘着剤の滲み出しや貼付
剤のずれが少ない。皮膚を屈伸しても、貼付剤がずれる
こともない。貼付剤の剥離後に、粘着剤が皮膚に残留す
ることもない。従って、この貼付剤によれば、患者は、
痛みゃ不快感を感じ42−
ることがなくなる。貼付剤中の粘着剤のTg値と、補強
性繊維質充填剤とを組合せることにより、粘着剤の素材
として用いられる物質の選択範囲も広げられる。Therefore, if this patch is used, the efficacy of the drug will be increased and the utilization efficiency of the drug will be increased. It is also economical because a large amount of drug can be contained in one patch. Furthermore, even when this patch is applied to the skin of a human body, there is little oozing of the adhesive or slippage of the patch. Even if the skin is flexed and stretched, the patch will not shift. No adhesive remains on the skin after the patch is removed. Therefore, according to this patch, the patient can:
You will no longer experience pain or discomfort. By combining the Tg value of the adhesive in the patch and the reinforcing fibrous filler, the selection range of substances used as the material for the adhesive can be expanded.
以上that's all
Claims (1)
、 該粘着剤層は、ガラス転移温度(Tg)が−71℃以下
である粘着剤、補強性繊維質充填剤、および薬剤を含有
し、該粘着剤は(メタ)アクリル酸エステルポリマーか
ら主として構成され、該粘着剤層の保持力値(H)およ
び粘着力値(F)は以下のa式およびb式の関係を満足
する貼付剤。 H/F>0.3(秒/g)・・・a F>200(g)・・・b[Claims] 1. A patch having a backing support layer and an adhesive layer, the adhesive layer comprising an adhesive having a glass transition temperature (Tg) of -71°C or lower, and a reinforcing fibrous filler. The pressure-sensitive adhesive is mainly composed of a (meth)acrylic acid ester polymer, and the holding force value (H) and adhesive force value (F) of the pressure-sensitive adhesive layer are expressed by the following formulas a and b. A patch that satisfies the following relationships. H/F>0.3 (sec/g)...a F>200(g)...b
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1267313A JP2512564B2 (en) | 1989-10-13 | 1989-10-13 | Patch |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1267313A JP2512564B2 (en) | 1989-10-13 | 1989-10-13 | Patch |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH03127726A true JPH03127726A (en) | 1991-05-30 |
JP2512564B2 JP2512564B2 (en) | 1996-07-03 |
Family
ID=17443087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP1267313A Expired - Fee Related JP2512564B2 (en) | 1989-10-13 | 1989-10-13 | Patch |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2512564B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0591432A1 (en) † | 1991-06-27 | 1994-04-13 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
-
1989
- 1989-10-13 JP JP1267313A patent/JP2512564B2/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0591432A1 (en) † | 1991-06-27 | 1994-04-13 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
EP0591432B2 (en) † | 1991-06-27 | 2010-11-10 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Also Published As
Publication number | Publication date |
---|---|
JP2512564B2 (en) | 1996-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002214364B2 (en) | Transdermal drug delivery system with improved water absorbability and adhesion properties | |
JPH05194201A (en) | Pressure-sensitive silicone adhesive composition for use in percutaneous drug administration apparatus and related medical appliance | |
EP1928924A1 (en) | Acrylic polymer-based adhesives | |
KR20070008676A (en) | Crosslinkable pressure-sensitive adhesive for the skin | |
JP4195375B2 (en) | Pyrrolidonoethyl (meth) acrylate containing pressure sensitive adhesive composition | |
CA2004049C (en) | Topical application of medicament in a binder | |
JP2512565B2 (en) | Patch | |
EP1945685A1 (en) | Acrylic polymer-based adhesives | |
JPH0228978B2 (en) | ||
JP4799783B2 (en) | Elastic patch | |
JPH07116023B2 (en) | Patch using polyurethane film as support | |
JPH03127726A (en) | Pasting agent | |
JP2512563B2 (en) | Patch | |
JPS597689B2 (en) | pharmaceutical formulations | |
JPS597687B2 (en) | medical parts | |
JP3055991B2 (en) | External pharmaceutical preparation | |
JPH0672879A (en) | Aspirin-containing percutaneously absorbable preparation | |
JP2572133B2 (en) | Patch | |
JPS63150363A (en) | Hydrophilic self-adhesive composition | |
JPH11349476A (en) | Medical pasting material | |
JP2554751B2 (en) | Patch | |
JPH0565224A (en) | Gelatinous material and therapeutic gel pharmaceutical using the same | |
JP2554752B2 (en) | Patch | |
JPS62263120A (en) | Plaster | |
JPH03112559A (en) | Adhesive |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
LAPS | Cancellation because of no payment of annual fees |